Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

In development
Reference number: GID-TA12518
Expected publication date: 07 April 2027

Documents

Documents created during the development process.

Committee meetings

Committee meeting: 1

Invitation to participate

Final scope (PDF 174 KB)

Published:

08 July 2026
Final stakeholder list (PDF 136 KB)

Published:

08 July 2026
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 363 KB)

Published:

08 July 2026
Equality impact assessment (scoping) (PDF 93 KB)

Published:

08 July 2026

Notes

This is the deferred appraisal of D5. Scoping documents can be found on the record for D5. The appraisal is expected to begin in early July 2026.